Application of serum-free culture medium in culturing cancer tissue origin spheroids
A serum-free medium and culture medium technology, applied in the field of cell culture, can solve the problems of limited proliferation, large cell loss and slow proliferation of CTOS culture, and achieve stable and controllable culture conditions
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0073] Embodiment 1 A kind of serum-free culture medium
[0074] Each component and its final concentration: basal medium DMEM / F12; BSA, 1.55% (w / v); Y27632, 10μM; B27 (50×), 2% (v / v); Heregulin, 10ng / ml; EGF , 50ng / ml; bFGF, 8ng / ml; Activin A, 10ng / ml; Nicotinamide, 10mM; NEAA (100×), 1% (v / v); Trace Elements A (1000×), 0.1% (v / v); TraceElements B (1000×), 0.1% (v / v); Trace Elements C (1000×), 0.1% (v / v); 2-mercaptoethanol, 0.1 mM; Primocin, 100 μg / ml.
Embodiment 2
[0075] Embodiment 2 A kind of serum-free culture medium
[0076] Components and their final concentrations: basal medium DMEM / F12; BSA, 0.1% (w / v); Y27632, 1 μM; B27 (50×), 0.1% (v / v); Heregulin, 1ng / ml; EGF , 1ng / ml; bFGF, 1ng / ml; Activin A, 1ng / ml; Nicotinamide, 1mM; NEAA (100×), 0.1% (v / v); Trace Elements A (1000×), 0.01% (v / v); TraceElements B (1000×), 0.01% (v / v); Trace Elements C (1000×), 0.01% (v / v); 2-mercaptoethanol, 0.01 mM; Primocin, 50 μg / ml.
Embodiment 3
[0077] Embodiment 3 A kind of serum-free culture medium
[0078]Each component and its final concentration: basal medium DMEM / F12; BSA, 10% (w / v); Y27632, 50μM; B27 (50×), 10% (v / v); Heregulin, 100ng / ml; EGF , 200ng / ml; bFGF, 100ng / ml; Activin A, 100ng / ml; Nicotinamide, 100mM; NEAA (100×), 10% (v / v); Trace Elements A (1000×), 1% (v / v); TraceElements B (1000×), 1% (v / v); Trace Elements C (1000×), 1% (v / v); 2-Mercaptoethanol, 1 mM; Primocin, 500 μg / ml.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


